Zai Lab Ltd
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $ZLAB in the last 30 days.
See all $ZLAB insider activity →Cantor Fitzgerald reiterated an Overweight rating and $37 price target for Zai Lab (ZLAB), citing potential for its DLL3 ADC, zocilurtatug, in small cell lung cancer. The stock is up 45% year-to-date. Zai Lab's Q2 earnings beat expectations with $106.3M revenue and adjusted EPS of -$0.05. Analysts maintain a Strong Buy consensus with price targets ranging from $24.25 to $50.
Zai Lab (ZLAB) will present global clinical trial data on zocilurtatug pelitecan (zoci) for first-line extensive-stage small cell lung cancer (ES-SCLC) at ESMO Congress 2026. The trial evaluates zoci in combination with atezolizumab with or without carboplatin. An investor call is scheduled for October 23, 2026, to discuss the data and future plans. Zai Lab highlights zoci's potential as a backbone ADC in ES-SCLC treatment.
Zai Lab (ZLAB) and Argenx reported positive Phase 3 results for VYVGART Hytrulo in treating autoimmune myositis, showing significant improvements over placebo. The data suggest potential for the drug in a market currently dominated by corticosteroids. Analysts highlight the importance of execution on recent launches and China's pricing pressures. Some analysts predict modest revenue growth and continued losses by 2029.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning ZLAB (Zai Lab Ltd). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent ZLAB coverage spans technology, earnings and financial news.
Analyst reiteration may provide modest upside pressure.
Positive trial data could lift Zai Lab shares as investors price in potential efficacy and future sales.
Positive Phase 3 data could boost Zai Lab's valuation and drive near‑term buying pressure.
Results underscore ZLAB's reliance on partner data and may pressure the stock amid loss concerns.
Positive Phase 3 topline data in a subtype with no approved therapy increases commercialization and regulatory optionality for Zai Lab’s Greater China rights.
AlphAI scores every news story that mentions ZLAB with an AI model for sentiment and relevance, and aggregates insider trades from Zai Lab Ltd's SEC EDGAR Form 4 filings. Figures refresh continuously.
Cantor Fitzgerald reiterated an Overweight rating and $37 price target for Zai Lab (ZLAB), citing potential for its DLL3 ADC, zocilurtatug, in small cell lung cancer. The stock is up 45% year-to-date. Zai Lab's Q2 earnings beat expectations with $106.3M revenue and adjusted EPS of -$0.05. Analysts maintain a Strong Buy consensus with price targets ranging from $24.25 to $50.
1 min readZai Lab (ZLAB) will present global clinical trial data on zocilurtatug pelitecan (zoci) for first-line extensive-stage small cell lung cancer (ES-SCLC) at ESMO Congress 2026. The trial evaluates zoci in combination with atezolizumab with or without carboplatin. An investor call is scheduled for October 23, 2026, to discuss the data and future plans. Zai Lab highlights zoci's potential as a backbone ADC in ES-SCLC treatment.
2 min readZai Lab (ZLAB) and Argenx reported positive Phase 3 results for VYVGART Hytrulo in treating autoimmune myositis, showing significant improvements over placebo. The data suggest potential for the drug in a market currently dominated by corticosteroids. Analysts highlight the importance of execution on recent launches and China's pricing pressures. Some analysts predict modest revenue growth and continued losses by 2029.
3 min readArgenx (ARGX) and Zai Lab (ZLAB) reported positive Phase 3 results for VYVGART Hytrulo in autoimmune myositis. ARGX saw a 15% stock rise and a $1,100 price target from RBC. ARGX reported Q2 2026 revenue of $1.516B, up 60% YoY, while ZLAB reported $106.3M revenue, down 3% YoY. ARGX has a stronger financial position with $5.2B in cash, while ZLAB has $717.5M. Investors should watch FDA decisions and ZLAB's commercial execution.
3 min readZai Lab (NASDAQ: ZLAB) and argenx (NASDAQ: ARGX) reported positive topline Phase 3 ALKIVIA results for efgartigimod (VYVGART Hytrulo) in autoimmune myositis. The study met the Week 52 primary endpoint in the combined IMNM and DM population (p=0.0011), with mean Total Improvement Score 47.95 vs 32.56 vs placebo. IMNM also met (p=0.0048); DM did not reach significance (p=0.1093).
4 min readZai Lab (ZLAB) reported Q2 2026 revenues of $106.3 million, down from $110.0 million a year earlier. Net product revenue was $105.8 million, up 11% sequentially, with growth tied to VYVGART and stabilization of ZEJULA. Net loss was $50.8 million ($0.05/share). Cash was $717.5 million at June 30, 2026. Management discussed Zoci and VYVGART timelines and supply constraints.
6 min readZai Lab Limited (NASDAQ:ZLAB) reported quarterly results with revenue of about $106m, 2.4% above analyst forecasts, and statutory loss of $0.46 per share, 2.4% smaller than expected. For 2026, 16 analysts’ consensus calls for revenue $422.9m (down from $447.6m) and loss $2.26 per share. Consensus price target stays near $32.18.
5 min readZai Lab (NASDAQ:ZLAB) said it plans to seek China NRDL inclusion for VYVGART HYTRULO and shift the VYVGART franchise from IV to subcutaneous. Management flagged timing effects on second-half revenue, aims to stabilize revenue before stronger 2027 growth, and reported $717.5M cash. It outlined zoci ADC Phase III plans and pipeline updates.
7 min readZai Lab Ltd (ZLAB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates – The Company advanced multiple global oncology and immunology programs toward key clinical and regulatory milestones, with significant pipeline catalysts expected in the second half
6 min readDu Ying (Chairperson & CEO) sold 7,026 shares of Zai Lab Ltd (ZLAB) at $18.53 ($0.13M total) on 2026-06-30.
1 min read
